Table 1.
Associations between MYPT1/CD31 combined expression and various clinicopathological parameters of patients with prostate cancer.
|
Clinicopathological
Parameters |
Case
no. |
MYPT1(low)/
CD31(high) (n, %) |
MYPT1(high)/
CD31(low) (n, %) |
MYPT1(low)/
CD31(low) (n, %) |
MYPT1(high)/
CD31(high) (n, %) |
P |
|---|---|---|---|---|---|---|
| Age (year) | ||||||
| < 66 | 155 | 40 (25.80) | 52 (33.50) | 35 (22.60) | 28 (18.10) | 0.238 |
| ≥66 | 77 | 21 (27.30) | 19 (24.70) | 15 (19.50) | 22 (28.60) | |
| Serum PSA (ng/ml) | ||||||
| <4 | 30 | 7(23.30) | 9(30.00) | 6(20.00) | 8(26.70) | 0.856 |
| ≥4 | 159 | 47(29.60) | 49(30.8) | 30(18.90) | 33(20.80) | |
| Gleason score | ||||||
| < 7 | 93 | 13(14.00) | 36(38.70) | 23(24.70) | 21(22.60) | 0.004 |
| ≥7 | 139 | 48(34.50) | 35(25.20) | 27(19.40) | 29(20.90) | |
| Pathological stage | ||||||
| T2A-T2C | 173 | 38(22.00) | 53(30.6) | 42(24.30) | 40(23.10) | 0.047 |
| T3A-T4 | 59 | 23(39.00) | 18(30.50) | 8(13.6) | 10(16.9) | |
| Metastasis | ||||||
| Negative | 212 | 55(25.90) | 68(32.10) | 47(22.20) | 42(19.80) | 0.125 |
| Positive | 20 | 6(30.00) | 3(15.00) | 3(15.00) | 8(40.900) | |
| Overall survival | ||||||
| Live | 187 | 43(23.00) | 61(32.60) | 43(23.00) | 40(21.40) | 0.102 |
| Death | 45 | 18(40.00) | 10(22.20) | 7(15.36) | 10(22.20) | |
| Biochemical recurrence | ||||||
| Negative | 146 | 31(21.20) | 54(37.00) | 32(21.90) | 29(19.90) | 0.022 |
| Positive | 86 | 30(34.90) | 17(19.80) | 18(20.90) | 21(24.4) |